Regenxbio Inc (NAS:RGNX)
$ 11.63 -0.48 (-3.96%) Market Cap: 574.79 Mil Enterprise Value: 392.45 Mil PE Ratio: 0 PB Ratio: 1.65 GF Score: 69/100

Regenxbio Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript

May 12, 2021 / 04:30PM GMT
Release Date Price: $34.81 (-2.71%)
Alec Warren Stranahan
BofA Securities, Research Division - Associate

Hey, everyone. Good afternoon and welcome to Day 3 of the BofA Health Care Conference. Thanks for joining the session with REGENXBIO. My name is Alec Stranahan, I'm an analyst on the U.S. bio pharma team here at BofA. And I'm pleased to be joined today by Ken Mills, President and CEO of REGENXBIO.

And I believe Ken is going to run through some initial comments to start, and then we'll jump into some Q&A. So with that, Ken, over to you.

Kenneth T. Mills
REGENXBIO Inc. - President, CEO & Director

Thanks, Alec. Appreciate the invitation as always from you and the BofA team and the good work to put this conference on in the virtual format.

Just an introduction to REGENXBIO, for those of you that know us and don't know us, we've been a leader in the gene therapy field for more than a decade, focused on development of what we think are highly curative potential AAV gene therapies. Inside the company, we're advancing a broad pipeline programs with multiple ongoing

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot